I believe option 1 is not viable due to political risks and option 2 is irrelevant; the 15% isn’t actually an export fee. It’s just 15% cut of all revenues derived from sales to China.
It can be done in the next three year window quietly. Look at Ireland and the pharmaceutical/tech setup there were no corporate announcement for the tax optimization
I believe option 1 is not viable due to political risks and option 2 is irrelevant; the 15% isn’t actually an export fee. It’s just 15% cut of all revenues derived from sales to China.
It can be done in the next three year window quietly. Look at Ireland and the pharmaceutical/tech setup there were no corporate announcement for the tax optimization